Combining CPI-613 with a GLS inhibitor CB-839, however, abrogates the dependency of HNSCC cells on glutamine, representing a novel synergistic strategy to overcome glutamine-addicted HNSCC. This evidence concerns the gene GLS and head and neck squamous cell carcinoma.